SCHEMBL2391552

SCHEMBL2391552

O=C(O)C(F)c1ccccc1-c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
PTPN1 P18031 2/20 0.40
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
PTPRC P08575 1/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
TTR P02766 1/20 0.39
GAA P10253 1/20 0.39
CNR2 P34972 1/20 0.38
ALDH1A1 P00352 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CTSA P10619 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19458984 0.84 CNR2 (0.50) NPSR1MEN1KMT2AMAPTCES2
SCHEMBL2395411 0.84 NPSR1 (0.46) NPSR1MEN1KMT2AMAPTPTPN1
SCHEMBL9103702 0.81 CES2 (0.47) NPSR1MEN1KMT2AMAPTCES2
SCHEMBL2391709 0.81 KMT2A (0.47) NPSR1MEN1KMT2AMAPTPTPN1
SCHEMBL11153495 0.80 PTGS2 (0.49) NPSR1MEN1KMT2AMAPTHPGD
SCHEMBL2393913 0.80 MAPT (0.42) NPSR1MEN1KMT2AMAPTPTPN1
SCHEMBL2393532 0.80 KMT2A (0.46) NPSR1MEN1KMT2AMAPTGAA
SCHEMBL2391431 0.79 SLC6A4 (0.45) NPSR1KMT2AMAPTPPARGPPARA
Hydrochloric Acid SCHEMBL27841046 0.79 MEN1 (0.41) NPSR1MEN1KMT2AMAPTCES2
SCHEMBL2395284 0.77 AKR1C3 (0.46) NPSR1MEN1KMT2AMAPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 NPSR1 2461/4885MEN1 1467/4885KMT2A 78/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 NPSR1 2461/4885MEN1 1467/4885KMT2A 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.